Latest News-BUCHAN CONSULTING PTY LTD Mediaroom_Page

Prota Therapeutics' CEO Mimi Tang honoured at BioMelbourne Network's Women in Leadership Awards 2024

MELBOURNE, Australia, April 29, 2024 /PRNewswire/ -- Prota Therapeutics' CEO ProfessorMimi Tang has...

2024-04-29 19:25 1267

Prota Therapeutics' CEO Mimi Tang honoured at BioMelbourne Network's Women in Leadership Awards 2024

MELBOURNE, Australia, April 29, 2024 /PRNewswire/ -- Prota Therapeutics' CEO ProfessorMimi Tang has...

2024-04-29 10:40 1571

Trajan's Microsampling Devices Meet IVDR Compliance in Europe, UK

Mitra® and hemaPEN® receive regulatory certification as medical devices for remote blood sample col...

2023-06-02 20:00 2843

Appendix 4C - Q2 FY23 Quarterly Cash Flow Report

Highlights: * Expanded participation in ATH434 Phase 2 clinical trial with sites opened for recr...

2023-01-31 20:25 3061

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy

U.S. now open for enrollment of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Austral...

2023-01-09 23:25 2242

Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation)

MELBOURNE, Australia and SAN FRANCISCO, Jan. 6, 2023 /PRNewswire/ -- Alterity Therapeutics Limited ...

2023-01-06 20:25 3759

Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum

MELBOURNE, Australia and SAN FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: AT...

2023-01-03 23:25 1636

Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office

- Patent covers more than 100 novel compounds targeting neurodegenerative diseases including Parkin...

2022-12-29 23:25 2643

Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO, Nov. 7, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: AT...

2022-11-07 23:25 2485

Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO , Oct. 26, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ...

2022-10-26 19:25 2154

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy

Australia now open for study of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Austral...

2022-10-13 22:25 1272

Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson's Disease and Movement Disorders

- Wearable sensors strongly correlated with clinical scales on motor impairment - - bioMUSE Study ...

2022-09-26 19:25 1582

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy

Regulatory Authorization Granted to Proceed with ATH434 Phase 2 Clinical Trial MELBOURNE, Australia...

2022-09-20 19:25 1460

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe

Second region now open for enrolment for rare, rapidly progressive, neurodegenerative disease MELB...

2022-08-25 19:25 2492

Alterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash Flow Report

* Phase 2 clinical trial for ATH434 commences in New Zealand and patient enrolment begins * Reg...

2022-07-22 19:25 1638

Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, July 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: AT...

2022-07-06 23:00 2286

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy

MELBOURNE, Australia and SAN FRANCISCO, June 23, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: A...

2022-06-23 23:00 2368

Trajan to acquire leading chromatography consumables and tools business building critical mass in the gas chromatography portfolio

Highlights * Trajan to acquire Chromatography Research Supplies, Inc. (CRS), a leading global ma...

2022-06-19 22:15 2440

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy

Multiple System Atrophy is a rare, rapidly progressive, neurodegenerative disease that causes profo...

2022-06-02 20:00 2419

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom

MELBOURNE, Australia, April 27, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE)...

2022-04-27 19:40 1625